Breast cancer
Progression after CDK4/6i + ET for HR+ HER2- MBC. What now?Marina (58 years old)
Marina, 58 years old make-up artist, had spent decades perfecting the art of transformation, painting confidence onto faces that had long forgotten their beauty.
She was diagnosed with primary metastatic breast cancer 16 months ago.
Assessment summary:
- Postmenopausal
- No family history of breast cancer
- No relevant medical history, ECOG PS: 0
- Diagnosed with primary metastatic breast cancer 16 months ago
- Imaging:
- 5 cm tumour in the right breast, 4 suspicious axillary lymph nodes
- Multiple suspicious lesions in bones and pleura
- Tumour biology: NST, ER 90%, PgR 70%, HER2 IHC 0, G2
Treatment with letrozole and CDK4/6i was started 1 month after diagnosis, which resulted in regression of bone and pleural metastases 3 months later and stable disease after 6 additional months.
Again 6 months later, i.e. 15 months after the start with letrozole and CDK4/6i:
- Imaging:
- Pleura: stable disease, bones: progression, new liver metastasis
- Biopsy of liver metastasis: ER 70%, PgR 40%, HER2 IHC 0, G2
- Somatic PIK3CA mutation status: wild type
- Somatic ESR1 mutation status (on liquid biopsy): ESR1 mutated
- Germline BRCA mutation status: wild type